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Using EHRs for Heart Failure Therapy
Recommendation Using Multidimensional
Patient Similarity Analytics
Maryam Panahiazar, Ph.D.* , Vahid Taslimitehrani* , Naveen L. Pereira, M.D.†
and Jyotishman Pathak, Ph.D.*
*
Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN,
USA
†
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
Abstract. Electronic Health Records (EHRs) contain a wealth of information
about an individual patient’s diagnosis, treatment and health outcomes. This
information can be leveraged effectively to identify patients who are similar to
each for disease diagnosis and prognosis. In recent years, several machine learning
methods 1 have been proposed to assessing patient similarity, although the
techniques have primarily focused on the use of patient diagnoses data from EHRs
for the learning task. In this study, we develop a multidimensional patient
similarity assessment technique that leverages multiple types of information from
the EHR and predicts a medication plan for each new patient based on prior
knowledge and data from similar patients. In our algorithm, patients have been
clustered into different groups using a hierarchical clustering approach and
subsequently have been assigned a medication plan based on the similarity index to
the overall patient population. We evaluated the performance of our approach on a
cohort of heart failure patients (N=1386) identified from EHR data at Mayo Clinic
and achieved an AUC of 0.74. Our results suggest that it is feasible to harness
population-based information from EHRs for an individual patient-specific
assessment.
Keywords: patient similarity; electronic health records; heart failure.

Introduction
In Precision Medicine, the ability to match the right drug with the right dose to the right
patient at the right time is vital2. This could be facilitated with the comparison of a new
patient with patients having similar characteristics such as co-morbidities and
pharmacotherapies. In the recent past, several statistical and machine learning methods
have been proposed3,4 for analyzing patient similarity. However, the focus has
primarily been on applying diagnosis data from EHR for the learning task. In this work,
we adopt a more holistic view, and consider different sources of information from EHR
including lab results, medications, comorbidities and demographics to develop a multidimensional approach for assessing patient similarity using machine learning
techniques. The similarity assessment has the potential to aid clinical decision-making
and therapy recommendation at the point-of-care. In particular, we applied a multidimensional patient similarity technique to investigate response to therapy in patients
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diagnosed with Heart Failure (HF) using various characteristics In the following
sections, we describe our methodology for multi-dimensional similarity assessment and
present preliminary findings on a cohort of HF patients (N=1386) derived from EHR
data at Mayo Clinic.

1.

Methods

In this study, we consider following variables from the EHR data to study and
categorize the patients:
• Lab results including Lymphocytes, Cholesterol, Sodium and Hemoglobin.
• Medications including Angiotensin Converting Enzyme (ACE) inhibitors,
Angiotensin Receptor Blockers (ARBs), β-adrenoceptor antagonists, (β-blockers),
Statins, and Calcium Channel Blockers (CCBs).
• Demographics including age, gender, ethnicity and race.
• 26 co-morbid conditions as defined by the Chronic Conditions Data Warehouse from
the Center for Medicare and Medicaid Services.5
• Echocardiogram measurements including ejection fraction.
• Vital signs including blood pressure, and body mass index (BMI).
For identifying a cohort of HF patients, we applied four eligibility criteria: (1) A
diagnosis of HF based on the ICD-9-CM code (428.x); (2) An ejection fraction (EF)
measurement less than 50% within one month of the HF diagnosis; (3) Another EF
measurement between 6 months and 15 month after the first EF measurement; and (4)
No prior diagnosis of coronary artery disease, myocarditis, cardiomyopathy and aortic
or mitral stenosis. From a cohort of 119,749 Mayo Clinic patients between 1993 and
2013, we identified 7827 patients with a diagnosis of HF (criteria 1). After applying
criteria 2--4 and excluding 673 patients due to incomplete data, our final study cohort
had N=1386 patients with HF. Table 1 represents the characteristics of the study cohort.
We developed the following criteria to define response to HF therapy: Patients are
under the “poor” response to therapy cateogory if the individual has less than 10%
increase in their EF measurement(s) within 12 months after HF treatment initiation.
Patients are under the “good” response to therapy category if the individual has at least
10% increase in their EF measurement(s) within 12 months after HF treatment
initiation.
We designed two different approaches to measure the patient similarity and
prediction of an appropriate treatment plan. The main difference between these two
approaches is the way we cluster the patients. In the first approach, we cluster patients
using two standard clustering algorithms (K-means and hierarchical clustering) 6 and in
the second approach, patients are clustered using a supervised technique based on the
medication plan. We summarize these approaches as follows: (1) Split patients based
on their response to medication (Good vs. Poor response categories as defined above).
(2) Cluster patients that responded to medication using two different techniques:
unsupervised and supervised (a) Unsupervised clustering including k-means and
hierarchical clustering and (b) Supervised clustering using the medication plan as class
variable. (c) Assign a label to each cluster, if the clustering is done by the unsupervised
technique. We identified the label of each cluster based on the most frequent
medication plan. (d) Measure the similarity of the new patient with each cluster created
in the previous steps in order to determine the medication plan of each new patient. To
measure the similarity of a new patient with each cluster, we propose a generalized
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Table 1: Patient Characteristics for Heart Failure Study Cohort (N=1386 unique patients)
Characteristics
Age (years)
Sex (male)
Race (White)
Ethnicity
BMI
Ejection Fraction (EF) %
Hemoglobin g/dL
Sodium mEq/L
Cholesterol mg/dL
Lymphocytes x10(9)/L
Asthma

Value
77 13
65
96%
90
28.4 10.8
37 9.8
13 1.9
140 6.9
155 42
1.53 0.78
9%

Characteristics
Myocardial infarction
Acquired hypothyroidism
Alzheimer
Atrial fibrillation
Anemia
Benign prostatic
Breast Cancer
Chronic Kidney Disease
Cataract
Colorectal Cancer
Diabetes

Value
28.1%
15.9%
49.9%
50.8%
10.3%
1.2%
53.2%
28.2%
0.9%
40.6%

Characteristics
Depression
Glaucoma
Hypertension
Hyperlipidemia
Ischemic heart
Osteoporosis
Prostate cancer
Pulmonary disease
Rheumatoid Arthritis
Stroke
Sys Blood Pres.

Value
22%
8.6%
82.8%
78.9%
71.2%
12.7%
6%
24.9%
38.6%
11.4%
121 23

Mahalanobis distance7. (e) Rank the similarities and choose the most similar cluster to
the new patient. And finally, (f) Recommend the medication plan of the most similar
cluster to the new patient.

to represent the feature vector of patient ,
We use   , , … , , 
where  1, … , and is the number of patients and  is the number of features.  is
the label assigned to the patient with  1,2, … ,  and  is number of class labels
and in our case, the number of medication plans. Medication plan is based on using
drug or combination of drugs with specific dosages during the treatment. The
generalized Mahalanobis distance between patient  and cluster  with means
   , … ,   are defined as follows
  ,        

where 
is a Symmetric Positive Semi-Definite (SPSD) matrix. We use the
Mahalanobis distance to measure the similarity between a patient and a cluster of
patients to find out which cluster is the most similar ones to selected patient.

2.

Results

Our objective in this study was to propose an approach to use patient similarity
techniques in order to determine the medication plan for a new patient based on the
EHR data. To this end, we defined a patient similarity framework, allowing us to
exploit the similarity based medication recommendation. We calculated the distribution
of medication plans in our cohort. 57% (N=790) of the patients responded to HF
therapy and their EF measurements increased by at least 10% after six months from the
first EF measurement and initiation of HF therapy. In our cohort, we detected 28
different medication plans as combination of 5 medication classes. The results show
that the combination of ACEIs, BBs and Statins is the most popular medication plan in
our cohort with 17% (N=241) of the patients being prescribed this combination therapy,
and with more than 50% (N=118) demonstrating an improvement in EF by at least
10%. The next common plan is ACEIs and BBs. More than 12% (N=166) of the
patients were prescribed ACEIs and BBs and 51% (N=85) of the patients demonstrated
good response to therapy. Note that statins and BBs are commonly prescribed to HF
patients, which affirm the clinical practice guidelines. Figure 1 represents the frequency
of medication plans across different EF intervals. Each figure shows the first 5 frequent
medication plans for specific EF values less than 50%.
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Figure 1: a) Medication Plans for Patients with EF<10%, b) Medication Plans for Patients with 10% <= EF
<20%, c) Medication Plans for Patients with 30%<=EF<40%, d) Medication Plans for Patients with 40% <=
EF < 50%

We calculated the AUC values for validating three different clustering approaches
(supervised
clustering=0.74,
hierarchical
clustering=0.71
and
k-means
clustering=0.69). To obtain robust area under curve (ROC) and avoid any chance of
over fitting, we performed 10 fold cross validation in each run such that 70% (N=970)
of the cohort was used to cluster patients and the remaining 30% (N=416) for testing
and determining the medication plan. Then, we considered different cut points starting
from 50% and finally calculated the average for each fold.
Regarding the validation process, it is noticeable that the training patients are
clustered using different methods and then a medication plan is assigned to each test
patient based on the similarity assessment. For unsupervised clustering, the number of
clusters (N=7) in both k-means and hierarchical clustering is determined by cross
validation analysis. Whereas for supervised clustering, due to a larger number of
clusters (N=28) we applied agglomerative clustering to merge the smaller clusters with
the bigger ones. If the number of patients under a specific medication plan or cluster is
less than 5% of the whole population, we called it small cluster and merged it with one
of the large clusters (more than 5% patients).
Our criterion to find a match to merge for each small cluster is similarity between the
elements of each plan. For example, {Statins, CCB, ACE} as a small cluster is merged
with {Statins, CCB, ACE, BB}. Although it is possible that small clusters are related to
patients with very particular characteristics, we did not investigate those aspects in this
study.
Table 2: Performance of Different Approaches
Method
Supervised
Hierarchical
K-means

Specificity
0.85
0.79
0.74

Sensitivity
0.52
0.5
0.49

F1
0.58
0.56
0.54

Accuracy
0.77
0.73
0.71

AUC
0.74
0.71
0.69

Table 2 represents the performance of different approaches tried in our analysis.
The results suggest that high specificity of different approaches leads to the creation of
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that clusters are highly separated from each other and highly dense within each other..
Further, since in the first clustering approach, the patients are clustered using a
supervised approach, there is no error in the clustering part and the whole error is
related to the merging clusters and measuring the similarity between the patient and
cluster.

3.

Discussion

We applied patient EHRs for inferring an individual patient’s response to HF
therapy. For this task, we use patient-specific information from the EHR, including
medical co- morbidities, laboratory measurements, ejection fraction, vital status and
demographics to identify similar patients, and subsequently predict HF therapy
response. Even though our preliminary results are promising, they require further
validation in a larger cohort, potentially, across multiple different EHR systems.
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